Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.

about

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

P2860

Q28550645-3D3E9658-8748-4026-85A2-8AA5D476FDFE Q37452320-94E23BD6-FA34-452D-9BEB-21C82B18DFD8

P2860

Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.

Item

http://www.wikidata.org/entity/Q43602029

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

Differences in estrogen recept ...... us bilateral breast carcinoma.

@en

Differences in estrogen recept ...... us bilateral breast carcinoma.

@nl

type

Item

label

Differences in estrogen recept ...... us bilateral breast carcinoma.

@en

Differences in estrogen recept ...... us bilateral breast carcinoma.

@nl

prefLabel

Differences in estrogen recept ...... us bilateral breast carcinoma.

@en

Differences in estrogen recept ...... us bilateral breast carcinoma.

@nl

P1476

Differences in estrogen recept ...... us bilateral breast carcinoma.

@en

P2093

Akashi-Tanaka S

http://www.w3.org/2001/XMLSchema#string

Fukutomi T

http://www.w3.org/2001/XMLSchema#string

Hasegawa T

http://www.w3.org/2001/XMLSchema#string

Matsuo K

http://www.w3.org/2001/XMLSchema#string

Shimizu C

http://www.w3.org/2001/XMLSchema#string

Tsuda H

http://www.w3.org/2001/XMLSchema#string

P2860

Bilateral breast carcinoma versus unilateral disease. Review of 498 patients.

Tumourigenesis associated with the p53 tumour suppressor gene.

Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study.

Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients.

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer.

p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.

Nuclear p53 immunoreaction associated with poor prognosis of breast cancer.

P304

31-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JSO.1062

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11344480

http://www.w3.org/2001/XMLSchema#string

Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.

about

P2860

P2860

Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698